Literature DB >> 16338656

A knotty turnabout?: Akt1 as a metastasis suppressor.

Shannon L Wyszomierski1, Dihua Yu.   

Abstract

Akt is well known to enhance malignancy and is recognized as a key target for antineoplastic therapies. However, intriguing findings reported by Yoeli-Lerner et al. in the November 23, 2005 issue of Molecular Cell, suggest a novel, antimetastasis function of Akt: activation of Akt1 inhibited invasion in some cancer cells. One possible mechanism for this surprising phenotype was that Akt activated the E3 ubiquitin ligase HDM2, causing ubiquitination and degradation of NFAT, an invasion-promoting factor. These findings clearly justify further investigations and, if validated in vivo, call for reevaluation of some Akt-targeting therapeutic strategies currently under development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16338656     DOI: 10.1016/j.ccr.2005.11.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  14 in total

Review 1.  NFAT as cancer target: mission possible?

Authors:  Jiang-Jiang Qin; Subhasree Nag; Wei Wang; Jianwei Zhou; Wei-Dong Zhang; Hui Wang; Ruiwen Zhang
Journal:  Biochim Biophys Acta       Date:  2014-07-26

2.  Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.

Authors:  Sayaka Kemmochi; Hitoshi Fujimoto; Gye-Hyeong Woo; Kaoru Inoue; Miwa Takahashi; Kunitoshi Mitsumori; Masao Hirose; Akiyoshi Nishikawa; Makoto Shibutani
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-26       Impact factor: 4.553

3.  Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

4.  Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.

Authors:  Amer K Karam; Chintda Santiskulvong; Mirela Fekete; Sara Zabih; Carol Eng; Oliver Dorigo
Journal:  Cytoskeleton (Hoboken)       Date:  2010-08

5.  Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice.

Authors:  Soon-Kyung Hwang; Hwang-Tae Lim; Arash Minai-Tehrani; Eun-Sun Lee; Jongmin Park; Seung Bum Park; George R Beck; Myung-Haing Cho
Journal:  Am J Respir Crit Care Med       Date:  2009-03-12       Impact factor: 21.405

Review 6.  Akt1 in endothelial cell and angiogenesis.

Authors:  Payaningal R Somanath; Olga V Razorenova; Juhua Chen; Tatiana V Byzova
Journal:  Cell Cycle       Date:  2006-03-01       Impact factor: 4.534

Review 7.  Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness.

Authors:  Emmanuel Chautard; Zangbéwendé Guy Ouédraogo; Julian Biau; Pierre Verrelle
Journal:  J Neurooncol       Date:  2014-01-30       Impact factor: 4.130

8.  The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration.

Authors:  Nguan Soon Tan; Guillaume Icre; Alexandra Montagner; Béatrice Bordier-ten-Heggeler; Walter Wahli; Liliane Michalik
Journal:  Mol Cell Biol       Date:  2007-08-06       Impact factor: 4.272

9.  Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis.

Authors:  Cheng-Xiong Xu; Dhananjay Jere; Hua Jin; Seung-Hee Chang; Youn-Sun Chung; Ji-Young Shin; Ji-Eun Kim; Sung-Jin Park; Yong-Hoon Lee; Chan-Hee Chae; Kee Ho Lee; George R Beck; Chong-Su Cho; Myung-Haing Cho
Journal:  Am J Respir Crit Care Med       Date:  2008-02-28       Impact factor: 21.405

10.  Screening E3 substrates using a live phage display library.

Authors:  Zhengguang Guo; Xiaorong Wang; Huihua Li; Youhe Gao
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.